Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies-Reference-Cited by-同舟云学术

Discovery of AZD4573, a Potent and Selective Inhibitor of CDK9 That Enables Short Duration of Target Engagement for the Treatment of Hematological Malignancies

Published:2020-12-11 Issue:24 Volume:63 Page:15564-15590
ISSN:0022-2623
Container-title:Journal of Medicinal Chemistry
language:en
Short-container-title:J. Med. Chem.

Author:

Barlaam Bernard¹^ORCID,Casella Robert²,Cidado Justin³,Cook Calum⁴,De Savi Chris³,Dishington Allan¹,Donald Craig S.¹,Drew Lisa³,Ferguson Andrew D.⁵^ORCID,Ferguson Douglas³,Glossop Steve¹,Grebe Tyler³,Gu Chungang³,Hande Sudhir³,Hawkins Janet¹,Hird Alexander W.³,Holmes Jane¹,Horstick James³,Jiang Yun⁶,Lamb Michelle L.³^ORCID,McGuire Thomas M.¹,Moore Jane E.¹,O’Connell Nichole⁵,Pike Andy¹,Pike Kurt G.¹^ORCID,Proia Theresa³,Roberts Bryan¹,San Martin Maryann³,Sarkar Ujjal³,Shao Wenlin³,Stead Darren¹,Sumner Neil¹,Thakur Kumar³,Vasbinder Melissa M.³,Varnes Jeffrey G.³,Wang Jianyan²,Wang Lei⁶,Wu Dedong²,Wu Liangwei⁶,Yang Bin³^ORCID,Yao Tieguang⁶

Affiliation:

1. Oncology R&D, AstraZeneca, Cambridge, CB4 0WG, United Kingdom

2. Advanced Drug Delivery, Pharmaceutical Sciences, R&D, AstraZeneca, Boston, Massachusetts 02451, United States

3. Oncology R&D, AstraZeneca, Boston, Massachusetts 02451, United States

4. Oncology R&D, AstraZeneca, Macclesfield, SK10 2NA, United Kingdom

5. Discovery Sciences, AstraZeneca, Boston, Massachusetts 02451, United States

6. Pharmaron Beijing Co., Ltd., 6 Taihe Road BDA, Beijing, 100176, P. R. China

Publisher

American Chemical Society (ACS)

Subject

Drug Discovery,Molecular Medicine

Link